National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

Found 331 cases where Vaccine is HPV4 and Symptom is Death

Case Details

This is page 29 out of 34

Result pages: prev   20 21 22 23 24 25 26 27 28 29 30 31 32 33 34   next


VAERS ID: 664526 (history)  
Form: Version 1.0  
Age:   
Sex: Female  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2016-11-08
Entered: 2016-11-08
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEPA: HEP A (HAVRIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK UN / UN
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / UN
MNQ: MENINGOCOCCAL CONJUGATE (MENACTRA) / SANOFI PASTEUR - / UNK UN / UN
TDAP: TDAP (BOOSTRIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK UN / UN

Administered by: Unknown       Purchased by: Unknown
Symptoms: Death, Necrotising fasciitis, Toxic shock syndrome streptococcal
SMQs:, Toxic-septic shock conditions (narrow), Sepsis (narrow), Opportunistic infections (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: AUSA2016SA200341

Write-up: Initial unsolicited report received from the literature on 29 October 2016. This case is linked with 2016SA200325, 2016SA200331, 2016SA200332, 2016SA200333, 2016SA200334, 2016SA200335, 2016SA200336, 2016SA200337, 2016SA200338, 2016SA200339, 2016SA200340, 2016SA200342 (same literature article). The following is verbatim from the article: Abstract: Disinfection should be required for all skin penetrative procedures including parenteral administration of vaccines. This review analyses medically attended infectious events following parenteral vaccination in terms of their microbiological aetiology and pathogenesis. Like ''clean'' surgical site infections, the major pathogens responsible for these events were Staphylococcal species, implicating endogenous contamination as a significant source of infection. As 70% isopropyl alcohol swabbing has been shown to effectively disinfect the skin, it would be medico-legally difficult to defend a case of sepsis with the omission of skin disinfection unless the very low risk of this event was adequately explained to the patient and documented prior to vaccination. There was a significant cost-benefit for skin disinfection and cellulitis. Skin disinfection in the context of parenteral vaccination represents a new paradigm of medical practice; the use of a low cost intervention to prevent an event of very low prevalence but of significant cost. This case involves a female 11-year-old patient who was vaccinated with a dose of MENACTRA, a dose of HAVRIX, a dose of GARDASIL and a dose of BOOSTRIX (batch number, expiration date, dose, site and route of administration were not reported for all vaccines) on an unspecified date. Medical history and concomitant medications were not reported. On an unspecified date, following the vaccination the patient developed Necrotising fasciitis complicated by fatal GAS toxic shock syndrome. Patient''s Lab data and Corrective treatment was not reported. On an unspecified date patient died as Necrotising fasciitis complicated by fatal GAS toxic shock syndrome was reported. It was unknown if autopsy was done. Documents held by sender: none. Sender''s Comments: Necrotising fasciitis complicated by fatal GAS toxic shock syndrome is a potentially fatal illness caused by a bacterial toxin. Different bacterial toxins may cause toxic shock syndrome. The causative bacteria include Streptococcus pyogenes in this case. Toxic shock syndrome and necrotizing fasciitis are unlisted with MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE. These are the infection may be due to improper sterilization issue. More over the patient received four vaccine simultaneously hence role of the particular vaccine cannot be provided. Reported Cause(s) of Death: Necrotising fasciitis; Necrotising fasciitis complicated by fatal GAS toxic shock syndrome.


VAERS ID: 676300 (history)  
Form: Version 1.0  
Age:   
Sex: Female  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2016-11-21
Entered: 2016-11-21
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 3 UN / UN

Administered by: Other       Purchased by: Other
Symptoms: Brain neoplasm malignant, Death, Syncope
SMQs:, Torsade de pointes/QT prolongation (broad), Arrhythmia related investigations, signs and symptoms (broad), Cardiomyopathy (broad), Hypotonic-hyporesponsive episode (broad), Hypoglycaemia (broad), Non-haematological malignant tumours (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: WAES1611ECU009202

Write-up: This spontaneous report was received from a physician via company representative regarding a 15 year old female patient. The patient''s medical history, concurrent conditions and concomitant medications were not reported. On an unknown dates, the patient received the first and second dose of GARDASIL (Lot#, dose and route unknown). On an unknown date, after the second dose, the patient had a syncope, and then she completed the scheme (on an unknown date received the third dose). Then on an unknown date, the patient was diagnosed with a malignant neoplasm of cerebellum, this tumor was difficult to localize and on an unknown date she died. The cause of death was unknown. The outcome of the syncope was not provided. The patient''s mother reported to the physician she believed that somehow or coincidently the events were related to GARDASIL. The physician did not report causality assessment for the events. Upon internal review, the malignant neoplasm of cerebellum was considered serious as an other important medical event. Additional information has been requested.


VAERS ID: 670784 (history)  
Form: Version 1.0  
Age:   
Sex: Unknown  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2016-12-08
Entered: 2016-12-09
   Days after submission:1
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other       Purchased by: Unknown
Symptoms: Death, Paralysis
SMQs:, Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Conditions associated with central nervous system haemorrhages and cerebrovascular accidents (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: PH0095075131612PHL002945

Write-up: Information has been received from a physician (also a Merck employee) referring to unspecified number of patients of unknown age. The physician posted on social media and forwarded a video. The video reported as below: GARDASIL was a vaccine developed for human papillomavirus (HPV) by Pharma Giant Merck & Co. GARDASIL was approved by the food and drug administration (FDA) in 2006. Since not many people were getting vaccinated. The company moved to vaccine recommendation to infants. In 2013, the Government pulled-out the vaccine recommendation this was due to reports on "serious" adverse systematic reactions. A total of 503,657 adverse events had been reported. This included paralysis and death. The company wanted to market this sexually transmitted disease (STD) vaccine to infants (product use in unapproved population). The company had started trials on babies and was set to conclude by 2017. It was not know about safety until something had been around a long lime. It was valid for parents to ask why they should do it. The outcome of paralysis, adverse events and adverse systematic reactions was unknown. The reporter did not assess the causality. The reporter considered adverse systematic reactions were serious (medically significant). Upon internal review, paralysis and death were considered to be medically significant. Additional information has been requested.


VAERS ID: 677402 (history)  
Form: Version 1.0  
Age: 16.0  
Sex: Female  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2017-01-09
Entered: 2017-01-09
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN

Administered by: Unknown       Purchased by: Unknown
Symptoms: Arthropathy, Cardiopulmonary failure, Chest pain, Condition aggravated, Death, General symptom, Hepatic infection, Immune system disorder, Kidney infection, Lupus nephritis, Malaise, Oxygen saturation decreased, Pain in extremity, Renal disorder, Systemic lupus erythematosus
SMQs:, Cardiac failure (narrow), Liver infections (narrow), Systemic lupus erythematosus (narrow), Acute central respiratory depression (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (broad), Cardiomyopathy (broad), Chronic kidney disease (broad), Arthritis (broad), Respiratory failure (broad), Tendinopathies and ligament disorders (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Infective pneumonia (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2016-12-31
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Systemic lupus erythematosus
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: CO0095075131701COL001379

Write-up: This spontaneous report as received from secretary of health, during a radio interview refers to a 16 year old female patient. The patient''s current condition included systemic lupus erythematosus. There was no information on patient''s concomitant medication. On 2013 the patient was vaccinated with GARDASIL (Lot#, dose and route unknown) dose 1 for prophylaxis. On an unspecified date, the patient was vaccinated with second dose of GARDASIL (Lot#, dose and route unknown) as prophylaxis. According to the news, the patient''s father reported that after application of the second dose of Gardasil, the patient developed the following adverse events. On an unknown date the patient experienced hepatic infection (hospitalization and medically significant), systemic lupus erythematosus (death, medically significant and hospitalization), physical problems (hospitalization), pain in extremity (hospitalization), low oxygen saturation (hospitalization), chest pain (hospitalization) and constant crisis (general symptom) (hospitalization). On 31-DEC-2016 the patient experienced cardiopulmonary failure (death and medically significant) and died during dialysis session. The patient''s death was related with her immunological system problems related with erythematous systemic lupus that started in 2011 with the following symptoms: joint alterations. This disease leaded the patient to develop kidney problems (unspecified date) and then to develop lupus nephritis (unspecified date) (death, medically significant and hospitalization) for which she needed dialysis. The reporter confirmed the patient died from her systemic illness and her death was not associated scientifically to Gardasil. The outcome of lupus nephritis, systemic lupus erythematosus and cardiopulmonary failure was reported as fatal. The outcome of hepatic infection, malaise, pain in extremity, oxygen saturation decreased, chest pain, general symptom and kidney infection was unknown. Causality assessment of hepatic infection, systemic lupus erythematosus, cardiopulmonary failure, lupus nephritis, malaise, pain in extremity, oxygen saturation decreased, chest pain, general symptom and kidney infection was reported to be not related to GARDASIL. No further information was provided. Additional information is not expected, since there are no contact details. This case is linked with 2017PVCL0002 and 2017PVCL0003 (same reporter link). Company Causality Assessment: Based on the limited information currently available for this case, a reasonable possibility to suggest a relationship between Gardasil and the reported events cannot be established. The lack of medical substantiation precludes a proper causality assessment of this report. Company Comment- No changes to Gardasil product safety information are warranted at this time. Merck and Co., Inc., also known as MSD, continues to monitor the safety profile of this vaccine. Sender''s Comments: CO-009507513-1701COL001408.


VAERS ID: 681996 (history)  
Form: Version 1.0  
Age: 9.0  
Sex: Male  
Location: Foreign  
Vaccinated:2014-10-13
Onset:2014-11-12
   Days after vaccination:30
Submitted: 2017-02-09
   Days after onset:820
Entered: 2017-02-09
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. K004215 / UNK UN / UN

Administered by: Other       Purchased by: Unknown
Symptoms: Death, Respiratory distress
SMQs:, Anaphylactic reaction (broad), Acute central respiratory depression (broad), Hypersensitivity (broad), Respiratory failure (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2014-12-11
   Days after onset: 29
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Drug use for unknown indication
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: AT0095075131702AUT001916

Write-up: Information has been received from a physician via Health authority (Agency# AT-BASGAGES-170314) on 03-FEB-2017 regarding a 9 year old male patient. The patient''s medical history, concurrent conditions and concomitant medications were not reported. On 13-OCT-2014, the patient was vaccinated intramuscularly with GARDASIL unknown dosage for an unspecified indication. On 12-NOV-2014, the patient experienced respiratory distress. The patient died on 11-DEC-2014. The cause of death was reported as respiratory distress. Causality assessment was not provided by the reporter. Additional information is not expected as no further information can be obtained from the health authority. Reported Cause(s) of Death: respiratory distress.


VAERS ID: 686506 (history)  
Form: Version 1.0  
Age:   
Sex: Unknown  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2017-03-21
Entered: 2017-03-21
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / SYR

Administered by: Other       Purchased by: Unknown
Symptoms: Death, Off label use, Respiratory papilloma, Surgery
SMQs:

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Laryngeal papillomatosis; Pulmonary disorder; Respiratory papillomatosis
Preexisting Conditions: Medical History/Concurrent Conditions: Laryngeal papillomatosis (diagnosed due to progressive dysphonia); Respiratory papillomatosis (diagnosed due to progressive dysphonia)
Allergies:
Diagnostic Lab Data:
CDC Split Type: ES0095075131703ESP007027

Write-up: This spontaneous report has been received from a physician via a company medical advisor regarding a patient (gender and age not provided). The patient was diagnosed with respiratory (also reported as laryngeal) papillomatosis (HPV 6 and 11) when she was 2 and half years old due to progressive dysphonia. The patient had 43 surgeries between July 2005 and May 2013. The physician''s diagnose was juvenile recurrent respiratory (also reported as laryngeal) papillomatosis (HPV 6 and 11). In 2008, it was discovered that the patient had pulmonary involvement. On an unknown date the patient started therapies with GARDASIL (HPV vaccine) (solution for injection; dose, route and lot number not provided) for juvenile recurrent respiratory(also reported as laryngeal) papillomatosis (HPV 6 and 11) (off label use). Other suspect drug as adjuvant treatment included probenecid (manufacturer unknown), celecoxib, erlotinib hydrochloride and cidofovir (dose, frequency and lot number not provided) which were used for the same indication. The physician stated that the adjuvant treatment was usually reserved for the most serious cases with short intervals between surgeries (<4 months), wide extension (subglottis) and necessity of urgent surgeries. The patient did not improve during the time between surgeries and did not improve in the lesions severity. The physician stated that the patient had evolved disease in which the immunization intervals were not strictly followed. In 2014, the patient died due to worsening of the pulmonary evolution (onset date unspecified). It was unknown whether the autopsy was done. The physician stated that the juvenile recurrent respiratory papillomatosis was a rare disease with hospital and surgical dependency. The physician stated that there was not a curative treatment and the evolution was unpredictable. Upon internal review, the events of juvenile recurrent respiratory (also reported as laryngeal) papillomatosis (HPV 6,11) were determined to be medically significant due to required surgeries. This is one of several reports received from the same reporter. Additional information has been requested.; Sender''s Comments: ES-009507513-1703ESP007032: ES-009507513-1703ESP007041: ES-009507513-1703ESP007328:; Reported Cause(s) of Death: Worsening of the pulmonary evolution.


VAERS ID: 686519 (history)  
Form: Version 1.0  
Age:   
Sex: Female  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2017-03-21
Entered: 2017-03-21
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / SYR

Administered by: Other       Purchased by: Unknown
Symptoms: Death, Malignant respiratory tract neoplasm, Off label use, Respiratory papilloma, Surgery
SMQs:, Non-haematological malignant tumours (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Laryngeal papillomatosis
Preexisting Conditions: Medical History/Concurrent Conditions: Intubation difficult; Laryngeal papillomatosis; Respiratory papillomatosis; Tracheostomy
Allergies:
Diagnostic Lab Data:
CDC Split Type: ES0095075131703ESP007041

Write-up: This Spontaneous report has been received from two physicians via a company medical advisor regarding a female patient of unknown age. The patient was diagnosed with respiratory (also reported as laryngeal) papillomatosis (HPV 11) when she was 2 and half years old due to progressive dysphonia. In 1994, the patient had a tracheotomy performed, as it was impossible to intubate the patient. The patient had 40 surgeries between July 1993 and November 2011 and it was reported that she had had 45 interventions. The physician''s diagnose was juvenile recurrent respiratory (also reported as laryngeal) papillomatosis (HPV 11). On an unknown date, the patient started therapies with GARDASIL (solution for injection; dose, route and lot number not provided) for juvenile recurrent respiratory (also reported as laryngeal) papillomatosis (HPV 11) (off label use). Other suspect adjuvant therapies included celecoxib, acyclovir, lysozyme chloride, cidofovir, cimetidine and interferon (unspecified)(frequency,dose, route and lot number not provided) for the same indication. The physician stated that the adjuvant treatment was usually reserved for the most serious cases with short intervals between surgeries (<4 months), wide extension (subglottis) and necessity of urgent surgeries. The patient did not improve during the time between surgeries (reported as "interval of 2-4 months") and did not improve in the lesions severity. The physician stated that the patient had evolved disease in which the immunization intervals were not strictly followed. In 2013 , the patient died due to malignancy of the lung lesions. It was unknown whether the autopsy was done. The physician stated that the juvenile recurrent respiratory papillomatosis was a rare disease with hospital and surgical dependency. The physician stated that there was not a curative treatment and the evolution was unpredictable. Upon internal review, the events of juvenile recurrent respiratory (also reported as laryngeal) papillomatosis (HPV11) were determined to be medically significant due to required surgeries. This is one of several reports received from the same reporter. Additional information has been requested.; Sender''s Comments: ES-009507513-1703ESP007032: ES-009507513-1703ESP007027: ES-009507513-1703ESP007328:; Reported Cause(s) of Death: malignancy of the lung lesions.


VAERS ID: 688735 (history)  
Form: Version 1.0  
Age:   
Sex: Female  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2017-03-29
Entered: 2017-03-30
   Days after submission:1
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other       Purchased by: Unknown
Symptoms: Death
SMQs:

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: FJ0095075131703FJI013085

Write-up: This spontaneous media report received from an unspecified reporter was obtained during a review of a website and refers to 5 female patients of unspecified age. The patients concurrent conditions, medical history or concomitant medications were not reported. On an unspecified date, the patients were vaccinated with an unspecified dose of GARDASIL as prevention of cervical cancer (dose, route, anatomical location, lot number and expiration date were not reported). On an unknown date, it was reported that the patients died for unspecified reasons. Within the media report it was stated that it turns out that this vaccine, supposedly protecting against cervical cancer, could be the main killer of women. Firstly, there was no research showing that it really works. Second: the vaccine had been on the market since 2006, but no one has tested it on children under the age of 16. Third: It was issued that the medical records should be kept for as long as 10 years, unless it exists at all. Fourth: lack of complete monitoring system for vaccinated children. Fifth: the age of the vaccinated was reduced to the age of 12 and then to the age of 8. Sixth: girls of this age do not have developed sexual organs, so they are damaged during their development. This had been proven. Seventh: the boys were also started vaccinating, allegedly as viral carriers. The problem was that the virus also moves in the saliva and already the newborn baby can be infected with the kisses. Vaccination of an infected child accelerates the development of cancer. Eighth: 95% of the virus dies spontaneously within 6 months. The original work on HPV Gardasil / Silgard, summarizes: "Although HPV was found in cervical cancer, this was not a valid reason to confirm. Thus, other cofactors were essential for the progression of HPV cervical cancer." Long term use of hormonal contraceptives had a very high probability of this change, smoking and concomitant human immunodeficiency virus (HIV) infection have been identified as factors that significantly affect the onset of cancer. Concomitant Chlamydia trachomatis (CT) and herpes simplex virus type 2 (HSV-2), immunosuppression, and even some dietary deficiencies are likely to be responsible for cancer. Also genetic and host immune factors and viral agents such as viral variants and viral integration that may be important but not identified. Already after the first year of GARDASIL sales in 2006, more than 1,600 reports of complications were reported (1703FJI013081), of which 371 were reported as serious (1703FJI013082) and 42 cases were vaccination in pregnant women (1703FJI013083), of which 18 had miscarriage or fetal malformations (1703FJI013084). The Vaccination Information Center noted: 5 deaths of girls, 31 reports identified as life-threatening (1703FJI013086) and 1385 cases required acute medical intervention (1703FJI013087). In total, 2207 adverse effects were reported (1703FJI013088). The Journal of Medicine reported that GARDASIL may be more dangerous than it could have been. Comparison with MENACTRA (for meningitis) showed that: At least 2 times more need for home visits in children vaccinated with GARDASIL, four times more reports of fatalities were reported, 6 times more reports of syncope and 7 times more reports. A professor more bluntly defined about such mindless vaccinations to girls, not just boys: "It is not justified to vaccinate the whole population without the number of cases that can be reduced to a fraction of a cent." Correspondingly, cervical screening had virtually eliminated cervical cancer mortality. There were no complications such as those occurring after vaccination. The reporter stated that it should be strongly emphasized that vaccinations do not eliminate cytological tests. There are over 120 types of this virus. However, the authors of a book written specifically for the Internal Medicine Archives write: "Although the HPV virus has not yet grown, but by the use of molecular methods, different genotypes of the virus have been identified " and further: "As many as 120 of these genotypes have been identified but not always corresponding to serotypes. " In other words, despite over 40 years of research, the virus was uncovered. The government had "suspended" the program of vaccinating girls after 4 deaths (1703FJI013089). "The HPV vaccine was associated with serious adverse events with a high level of reported complication (1703FJI013090). Death and devastating illness have been confirmed (1703FJI013091). " Only in the period from 2010 to 2012 were Human papillomas, type 611,16,18 HPV4, as many as 1253 complications (1703FJI013092). Upon internal review, death was considered to be medically significant. The causal relationship between the events and therapy with GARDASIL was not reported. This is one of several cases from the same reporter. Additional information has been requested.; Sender''s Comments: FJ-009507513-1703FJI011425: FJ-009507513-1703FJI013081: FJ-009507513-1703FJI013082: FJ-009507513-1703FJI013083: FJ-009507513-1703FJI013084: FJ-009507513-1703FJI013086: FJ-009507513-1703FJI013087: FJ-009507513-1703FJI013088: FJ-009507513-1703FJI013089: FJ-009507513-1703FJI013090: FJ-009507513-1703FJI013091: FJ-009507513-1703FJI013092:; Reported Cause(s) of Death: death.


VAERS ID: 690023 (history)  
Form: Version 1.0  
Age:   
Sex: Unknown  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2017-04-11
Entered: 2017-04-11
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Other       Purchased by: Unknown
Symptoms: Death
SMQs:

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: GB0095075131704GBR003037

Write-up: This spontaneous report as received from the author of the online article refers to unspecified 6 patients of unknown age and gender. There was no information about the patients'' concurrent conditions, concomitant therapies or medical history provided. On unknown dates, the patients were vaccinated with GARDASIL (dose, route of administration, lot # and expiration date were not reported). On unknown dates, the patients died. The causes of patients'' deaths were not reported. The relatedness between the event and GARDASIL was not reported. Upon internal review, the event of patients'' death was considered to be medically significant. This is one of several reports received from the same reporter. Additional information is not expected as follow up was not required.; Sender''s Comments: GB-009507513-1704GBR002599: GB-009507513-1704GBR003032: GB-009507513-1704GBR003034: GB-009507513-1704GBR003035: GB-009507513-1704GBR003036: GB-009507513-1704GBR003038: GB-009507513-1704GBR003039: GB-009507513-1704GBR003040: GB-009507513-1704GBR003060: GB-009507513-1704GBR003033:


VAERS ID: 694354 (history)  
Form: Version 1.0  
Age:   
Sex: Unknown  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2017-05-15
Entered: 2017-05-15
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / UNK UN / SYR

Administered by: Other       Purchased by: Unknown
Symptoms: Death, Pulmonary embolism
SMQs:, Embolic and thrombotic events, venous (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: ZA0095075131705ZAF007293

Write-up: This spontaneous report was received from a consumer concerning a few patients of unknown gender and age. The patients'' medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patients were vaccinated with GARDASIL injection, (strength, dose, lot number and expiration date were not reported) for prophylaxis. On an unknown date, the patients developed pulmonary embolism. On an unknown date, the patients died. The cause of death was the pulmonary embolism. The causality between the event and the GARDASIL was not reported. Upon internal review, the event pulmonary embolism was determined to be medically significant. This is one of several reports received from the same source. Additional information has been requested. Sender''s Comments: ZA-009507513-1507ZAF012830. Reported Cause(s) of Death: pulmonary embolism.


Result pages: prev   20 21 22 23 24 25 26 27 28 29 30 31 32 33 34   next

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?EVENTS=ON&PAGENO=29&SYMPTOMS[]=Death_%2810011906%29&VAX[]=HPV4


Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166